TARS
Tarsus Pharmaceuticals, Inc.
$72.22
-1.39
(-1.89%)
Mkt Cap
3.11B
Volume
555,509
52W Range
53.89-91.53
Sector
Healthcare
Beta
0.54
EPS (TTM)
-1.09 USD
P/E Ratio
-51.50
Revenue (TTM)
606.33M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M | 0 | 0 | 0 |
| Net Income | (66.42M) | (115.55M) | (135.89M) | (62.09M) | (13.83M) | (26.81M) | (4.67M) | (1.32M) |
| EPS | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Free Cash Flow | (22.31M) | (84.59M) | (123.00M) | (49.54M) | 3.16M | (21.59M) | (3.85M) | (1.19M) |
| FCF / Share | -0.53 | -2.25 | -4.19 | -2.01 | 0.15 | -1.06 | -0.20 | -0.28 |
| Operating CF | (12.45M) | (83.03M) | (117.49M) | (49.03M) | 3.75M | (21.14M) | (3.67M) | (1.18M) |
| Total Assets | 562.16M | 376.99M | 265.49M | 227.86M | 178.91M | 171.97M | 58.32M | 2.39M |
| Total Debt | 93.64M | 72.45M | 30.22M | 20.21M | 1.89M | 831,000 | 164,000 | 0 |
| Cash & Equiv | 183.64M | 94.82M | 224.95M | 71.66M | 171.33M | 168.13M | 57.95M | 2.35M |
| Book Value | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M | 165.98M | (6.00M) | (1.35M) |
| Return on Equity | -0.19 | -0.51 | -0.69 | -0.32 | -0.08 | -0.16 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.91M | 162.05M | 151.67M | 118.70M | 102.66M | 78.33M | 66.41M | 48.12M | 40.81M | 27.61M | 13.08M | 1.87M |
| Net Income | (18.55M) | (6.97M) | (8.37M) | (12.59M) | (20.34M) | (25.12M) | (23.11M) | (23.42M) | (33.29M) | (35.73M) | (41.90M) | (39.15M) |
| EPS | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 | -0.60 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 |
| Free Cash Flow | 62.70M | (30.47M) | 12.97M | 16.35M | (30.39M) | (21.24M) | (27.25M) | (8.93M) | (15.44M) | (37.96M) | (39.34M) | (36.74M) |
| FCF / Share | 1.44 | -0.71 | 0.30 | 0.38 | -0.72 | -0.54 | -0.71 | -0.23 | -0.41 | -1.08 | -1.23 | -1.20 |
| Operating CF | 66.77M | (24.65M) | 19.33M | 18.26M | (29.39M) | (20.65M) | (22.18M) | (8.65M) | (14.40M) | (37.79M) | (39.34M) | (32.36M) |
| Total Assets | 611.14M | 581.13M | 562.16M | 534.56M | 494.99M | 500.75M | 376.99M | 376.30M | 376.84M | 349.28M | 265.49M | 268.33M |
| Total Debt | 88.66M | 88.68M | 93.64M | 82.51M | 72.45M | 72.37M | 72.45M | 72.34M | 72.18M | 30.52M | 30.22M | 30.13M |
| Cash & Equiv | 204.59M | 102.19M | 183.64M | 112.72M | 96.65M | 175.79M | 94.82M | 176.21M | 181.09M | 193.71M | 224.95M | 226.67M |
| Book Value | 346.73M | 348.95M | 343.43M | 335.08M | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M | 213.66M |
| Return on Equity | -0.05 | -0.02 | -0.02 | -0.04 | -0.06 | -0.07 | -0.10 | -0.10 | -0.13 | -0.13 | -0.21 | -0.18 |
TARS News
Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease
Tarsus to Participate in Upcoming Investor Conferences
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript